COLO.B.DK

625.8

+0.55%↑

GMAB.DK

1,759.5

+1.03%↑

HLUNB.DK

41.9

+1.6%↑

ZEAL.DK

425.4

-4.9%↓

AMBUB.DK

98.4

+0.36%↑

COLO.B.DK

625.8

+0.55%↑

GMAB.DK

1,759.5

+1.03%↑

HLUNB.DK

41.9

+1.6%↑

ZEAL.DK

425.4

-4.9%↓

AMBUB.DK

98.4

+0.36%↑

COLO.B.DK

625.8

+0.55%↑

GMAB.DK

1,759.5

+1.03%↑

HLUNB.DK

41.9

+1.6%↑

ZEAL.DK

425.4

-4.9%↓

AMBUB.DK

98.4

+0.36%↑

COLO.B.DK

625.8

+0.55%↑

GMAB.DK

1,759.5

+1.03%↑

HLUNB.DK

41.9

+1.6%↑

ZEAL.DK

425.4

-4.9%↓

AMBUB.DK

98.4

+0.36%↑

COLO.B.DK

625.8

+0.55%↑

GMAB.DK

1,759.5

+1.03%↑

HLUNB.DK

41.9

+1.6%↑

ZEAL.DK

425.4

-4.9%↓

AMBUB.DK

98.4

+0.36%↑

Search

Novo Nordisk A-S (Class B)

Затворен

338.3 -2.38

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

334.8

Максимум

346.55

Ключови измерители

By Trading Economics

Приходи

-2.5B

27B

Продажби

-1.2B

77B

P/E

Средно за сектора

14.639

35.733

EPS

5.96

Дивидентна доходност

3.25

Марж на печалбата

34.484

Служители

78,387

EBITDA

39B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+9.53% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

3.25%

3.13%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

238B

1.6T

Предишно отваряне

340.68

Предишно затваряне

338.3

Novo Nordisk A-S (Class B) Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

18.08.2025 г., 13:52 ч. UTC

Значими двигатели на пазара

GoodRx Partners With Novo Nordisk to Lower Cost of Weight-Loss Drugs

18.08.2025 г., 09:23 ч. UTC

Значими двигатели на пазара

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

18.08.2025 г., 09:23 ч. UTC

Значими двигатели на пазара

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

6.08.2025 г., 06:52 ч. UTC

Печалби

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues -- Update

6.08.2025 г., 06:21 ч. UTC

Печалби

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues

2.09.2025 г., 09:14 ч. UTC

Горещи акции

Stocks to Watch Tuesday: Nestlé, Novo Nordisk, Nvidia -- WSJ

21.08.2025 г., 08:49 ч. UTC

Печалби
Горещи акции

Stocks to Watch Thursday: Meta, Coty, Walmart, Novo Nordisk -- WSJ

18.08.2025 г., 09:23 ч. UTC

Горещи акции

Stocks to Watch Monday: Novo Nordisk, Soho House, UnitedHealth -- WSJ

8.08.2025 г., 05:32 ч. UTC

Пазарно говорене

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

7.08.2025 г., 11:32 ч. UTC

Печалби

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7.08.2025 г., 11:03 ч. UTC

Печалби

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7.08.2025 г., 10:41 ч. UTC

Печалби

Eli Lilly Stock Drops on Weight-Loss Pill Data Ahead of Earnings -- Barrons.com

6.08.2025 г., 20:34 ч. UTC

Печалби

Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday -- Barrons.com

6.08.2025 г., 08:45 ч. UTC

Печалби

Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress. -- Barrons.com

6.08.2025 г., 07:19 ч. UTC

Пазарно говорене
Печалби

Novo Nordisk Sales in Line, Boosted by One-Off Rebate -- Market Talk

6.08.2025 г., 05:50 ч. UTC

Печалби

Novo Nordisk: Gudiance Assumes Macroeconomic, Political Environment Won't Significantly Change Business Conditions During 2025

6.08.2025 г., 05:48 ч. UTC

Печалби

Novo Nordisk Declares Interim Dividend of DKK3.75 Vs DKK3.50

6.08.2025 г., 05:46 ч. UTC

Печалби

Novo Nordisk Will Continue to Invest in Expanding Direct-to-Patient Initiatives For Wegovy

6.08.2025 г., 05:38 ч. UTC

Печалби

Novo Nordisk 2Q Ozempic Drug Sales DKK31.8B Vs DKK28.88B

6.08.2025 г., 05:37 ч. UTC

Печалби

Novo Nordisk 2Q Wegovy Drug Sales DKK19.53B Vs DKK11.66B

6.08.2025 г., 05:36 ч. UTC

Печалби

Novo Nordisk 2Q Gross Margin 83.3% Vs 84.9%, Op Margin 43.5% Vs 38.1%

6.08.2025 г., 05:35 ч. UTC

Печалби

Novo Nordisk: Taking Measures to Sharpen Commercial Execution Further, Ensure Efficiencies in Cost Base

6.08.2025 г., 05:34 ч. UTC

Печалби

Novo Nordisk: Continues Global Rollout of Wegovy to More Markets, Investing in Commercial Activities

6.08.2025 г., 05:31 ч. UTC

Печалби

Novo Nordisk 2Q Net Pft DKK26.5B

6.08.2025 г., 05:31 ч. UTC

Печалби

Novo Nordisk 2Q Oper Pft DKK33.45B

6.08.2025 г., 05:31 ч. UTC

Печалби

Novo Nordisk 2Q Sales DKK76.86B

5.08.2025 г., 21:58 ч. UTC

Печалби

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5.08.2025 г., 17:26 ч. UTC

Печалби
Придобивния, сливания и поглъщания

Hims & Hers Had a Tough Quarter. Weight-Loss Drugs Are Only One Problem. -- Barrons.com

5.08.2025 г., 15:15 ч. UTC

Печалби

Novo Nordisk Stock Catches a Downgrade. The Eli Lilly Threat Is Just One Reason. -- Barrons.com

5.08.2025 г., 10:07 ч. UTC

Пазарно говорене

Novo Nordisk's Facing Challenging Times -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Novo Nordisk A-S (Class B) Прогноза

Ценова цел

By TipRanks

9.53% нагоре

12-месечна прогноза

Среден 1,162.73 DKK  9.53%

Висок 1,550 DKK

Нисък 720 DKK

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Novo Nordisk A-S (Class B) през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

11 ratings

7

Купи

2

Задържане

2

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
help-icon Live chat